5 November 2026

When Adult Lead-In Trials Are Not an Option: Ethical & Regulatory Considerations for Pediatric Gene Therapy

A child sleeping in a hospital bed with an IV line in her hand, held by an adult caregiver, illustrating the clinical setting and patient population at the center of pediatric gene therapy research.

For most investigational therapies, the path to a pediatric trial runs through an adult trial first in order to afford additional protection to children. Sponsors establish an initial safety and dosing profile in adults, then adapt the protocol for younger populations. Gene therapies targeting conditions where patients do not survive to adulthood cannot follow this sequence. When the disease presents in early childhood and progresses rapidly, a trial in adults is not possible. Healthy adult volunteers would not be feasible or provide relevant safety information. Children are the only available study population from the start.

This creates a regulatory situation that many sponsors are unprepared for. The federal framework governing research involving children is not simply a modified version of the rules for adult research. It is a separate, tiered system with its own risk thresholds, consent requirements, and approval pathways. Sponsors who approach pediatric gene therapy trials with assumptions carried over from adult development programs tend to encounter constraints late in the process at the protocol stage, when redesign is costly and delays are measured in months.

Understanding this framework before protocol design begins is not just a compliance detail; it is a critical development strategy.

A Different Regulatory Framework for a Vulnerable Population

Federal regulations treat children as a protected class in research. Because children cannot fully understand or evaluate the risks of research participation, additional safeguards apply, and the standards for approvable risk exposure are more stringent than those that govern research with adults.

The foundations are the concepts of minimal risk and direct benefit. “Minimal risk” is defined in federal regulations as a probability and magnitude of harm or discomfort no greater than those ordinarily encountered in daily life or during routine physical or psychological examinations (45 CFR 46.102)1. For children, that standard is indexed to the experiences of average, healthy children in safe environments. It is a narrow category by design. “Direct benefit” means that the child may have a positive outcome from study participation, distinct from the indirect benefits of increased knowledge about the condition or the intervention.

Beyond that baseline, federal regulations establish four categories under which pediatric research can be approvable:

  • 45 CFR 46.404: Research involving no greater than minimal risk. No direct benefit to the child is required.
  • 45 CFR 46.405: Research involving greater than minimal risk, where there is the prospect of direct benefit to the individual participant. This is often interpreted as receipt of an investigational product that shows promise in the condition being studied, but may also apply to beneficial procedures or other interventions.
  • 45 CFR 46.406: Research involving greater than minimal risk but no direct benefit to individual participants, provided the risk rises only a minor increment beyond the minimal risk baseline, and the study is likely to yield generalizable knowledge about the child’s condition. The term “minor increase over minimal risk” is not defined in the regulations; interpretation is left to the IRB.2
  • 45 CFR 46.407: Research not otherwise approvable, but which presents an opportunity to understand or prevent a serious health problem affecting children. Research in this category cannot be approved by an IRB alone. It requires a special review meeting at the FDA, including public comment, before approval can be granted.

These categories determine more than approvability. They determine consent structure, specifically whether one parent/guardian or both parents/guardians must provide permission for a child to participate. The category an IRB assigns to a given protocol has direct downstream consequences for trial design and feasibility.

Where Sponsors Hit Roadblocks They Don’t Foresee

The pediatric research framework creates a category of studies that are approvable in competent adult participants but unapprovable in children. Healthy volunteer research is the clearest example: adults can enroll in studies that carry real risk and offer no prospect of direct benefit, because they can weigh that tradeoff and consent for themselves. Federal regulations do not permit that calculus to be applied on behalf of children. The same logic applies to placebo-group participants in pediatric trials. Because those children have no prospect of direct benefit, the framework imposes strict limits on the procedures to which they can be exposed.

The permissible risk exposure for both the healthy control group and the placebo group pediatric participants is therefore limited to what can be justified under 46.404 (no greater than minimal risk) or 46.406 (a minor increase above that baseline, with generalizable knowledge as justification). Any procedure that rises above that threshold is not approvable for healthy control or placebo-group pediatric subjects, regardless of how routine it may be in adult trials.

This is where the gap between adult and pediatric trial design tends to surface. Procedures that would be unremarkable in an adult placebo group may place a pediatric protocol in 46.407 territory, requiring FDA review and public comment before the study can proceed. The cost of discovering this at the IRB submission stage, rather than during protocol development, is significant in both time and resources.

Most IRBs approach this evaluation using a methodology called component analysis. Rather than weighing the risks and benefits of trial participation as a whole, the IRB examines each research procedure or intervention individually, asking whether that procedure, standing alone, offers the prospect of direct benefit and whether its risks are justified. Protocols that do not clearly distinguish between procedures performed solely for research purposes and those that would occur as part of standard care make this evaluation more difficult and introduce uncertainty that can slow the review process.3

Sponsors should also understand that the four-category framework applies across all pediatric research, not only to first-in-human or early-phase studies. It shapes IRB review regardless of the development phase.

What Sponsors Should Do Before Reaching the IRB

The practical implication of this framework is that protocol design for pediatric gene therapy trials cannot be separated from regulatory analysis. By the time a sponsor is ready to submit to an IRB, the protocol’s architecture has already determined which regulatory categories apply and whether the study, as designed, is approvable.

Sponsors developing gene therapies for pediatric-onset conditions should take several steps before a protocol reaches the IRB:

  • Identify which procedures are research-specific and which are standard of care (and would be performed even if the patient were not enrolled in the study). This distinction is central to how an IRB conducts component analysis. A protocol that does not make this clear invites uncertainty and slows review.
  • Engage the IRB early, during protocol development, rather than at submission. IRBs can provide guidance on where a proposed procedure is likely to fall within the risk category framework and flag potential 46.407 issues before they become design constraints requiring significant revision.
  • Come to the IRB with a proposed approach to assent. Assent, the child’s affirmative agreement to participate in addition to parental permission, is required for pediatric research and is handled with meaningful flexibility. Depending on the child’s age and developmental status, assent may be waived, or may be verbal rather than written, and the specific form it takes is something IRBs will work through with sponsors. Having a proposal based on thoughtful consideration of the patient population rather than waiting for direction makes this part of the process faster.
  • Build a safety-monitoring structure appropriate for a pediatric population with no established safety data.Gene therapies targeting pediatric-onset conditions often lack the adult safety database that informs standard monitoring approaches. The safety oversight structure (including, if appropriate, independent safety monitoring committees) and stopping rules need to be calibrated to that reality.

Start the IRB Conversation Before the Protocol Does

Pediatric gene therapy trials are not adult trials with a younger study population. They operate under a distinct regulatory framework that imposes meaningful constraints on protocol design, and those constraints are easiest to address when identified before design is complete.

With the level of complexity associated with pediatric gene therapy trials, sponsors who treat early IRB engagement as an optional courtesy are taking on timeline risk. In a clinical area where the stakes are already high, it is an entirely preventable one.

References

1 U.S. Department of Health and Human Services. 45 CFR 46 Subpart D: Additional Protections for Children Involved as Subjects in Research. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-d/index.html

2 Wendler D, Emanuel E. What is a “Minor” Increase over Minimal Risk? The Journal of Pediatrics, 147, 575–578. https://www.jpeds.com/article/S0022-3476(05)00679-7/fulltext

3 Truog RD. Ethical assessment of pediatric research protocols. Intensive Care Med. 2008 Jan;34(1):198–202. doi: 10.1007/s00134-007-0917-3. PMID: 17982740. https://pubmed.ncbi.nlm.nih.gov/17982740/

About the Authors:

Raffaella HartRaffaella Hart, MS, CIP, serves as Senior Vice President at BRANY, where she leads the organization’s IRB, IBC, and Quality Assurance services. A Certified IRB Professional (CIP) with over 25 years of experience in IBC and IRB administration, she was instrumental in achieving and maintaining BRANY IRB’s full AAHRPP accreditation. Hart holds a Master of Science in Healthcare Science with a focus in Clinical Research Administration from The George Washington University and a B.S. in Psychobiology from Binghamton University. Her work has been featured in IRB Advisor, Clinical Trials, The CenterWatch Monthly, The Monitor, and Seminars in Nuclear Medicine.

 

Linda ReuterLinda Reuter is the Sr. IRB Director at BRANY. Her responsibilities include supervising the IRB staff and maintaining compliance with the IRB Standard Operating Procedures as well as applicable regulations. This includes supervising pre- and post-IRB meeting activities, expedited reviews, continuing reviews, protocol monitoring, continuing education, development of short and long-term strategic goals for the organization, maintaining AAHRPP accreditation standards, policy maintenance and development, and training and mentoring of IRB staff. Ms. Reuter graduated with honors from SUNY Stony Brook with an M.S. in Health Sciences. She holds a B.S. in Biology from SUNY Stony Brook, and an advanced certificate in Health Care Management.